Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadunolimab + Gemcitabine + Carboplatin in Advanced TNBC
NCT05181462Phase 2Completed
- Sponsor
- Cantargia AB
- Start
- Jan 2022
- Primary completion
- Apr 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nadunolimab in triple-negative breast cancer (TNBC) (3 arms), sponsored by Cantargia AB. Primary endpoints: Dose Limiting Toxicity at 21 days and Objective Response Rate at 58 months. Started Jan 2022; status: completed.
02
Drugs
nadunolimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05181462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181462.